DarioHealth Earnings Call Highlights Pipeline, Profit Potential

DarioHealth ((DRIO)) has held its Q1 earnings call. Read on for the main highlights of the call.

DarioHealth’s latest earnings call struck a cautiously optimistic tone, highlighting improving unit economics, cost discipline and a growing commercial pipeline, even as the company continues to post losses and manage the overhang of a strategic review. Management framed 2026 as a key transition year, with near-term uncertainty but a clearer path to higher-margin, scaled channel revenue.

Sequential revenue growth signals early turnaround

DarioHealth reported Q1 2026 revenue of $5.6M, up from $5.2M in Q4 2025, marking roughly 7.7% quarter-over-quarter growth and a second straight quarter of sequential gains. Management positioned this as evidence that the business is stabilizing after a deliberate reset, with momentum expected to build as larger contracts start contributing.

Pipeline and new wins underpin growth story

The company showcased a commercial pipeline of about $127M across 241 open opportunities, underscoring what it called strong demand for its platform. DarioHealth added 85 new accounts in 2025, more than double its target, and signed 10 additional accounts in Q1 2026, most through partners, pointing to an expanding base for future recurring revenue.

Channel partnerships expand distribution reach

A central theme was the rapid scaling of its channel ecosystem, which currently provides access to more than 116M covered lives. With a new, largest-ever channel deal involving a major Northeastern hospital network, DarioHealth expects its potential reach to climb above 175M covered lives, including around 65M from the new partner and some 3,500 employer relationships.

High-margin B2B2C model supports profitability potential

Gross margin in Q1 came in at 57%, flat year-over-year but up from 54% in Q4 2025, while non-GAAP B2B2C gross margin held near 80% for the ninth straight quarter. Management highlighted these margins as proof that the core business can be highly profitable at scale, especially as more revenue flows through channel partners and digital offerings.

Cost cuts ease, but do not erase, losses

Operating expenses continued to trend lower, with total OpEx at $10.5M in Q1, down 21% from a year earlier and 8% sequentially, and non-GAAP OpEx at $8.7M, down 18% year-over-year. GAAP operating loss improved to $7.3M and non-GAAP operating loss to $5.3M, yet both figures underscore that DarioHealth still needs further scale and efficiency to reach breakeven.

Cash burn improves yet constrains aggression

The company ended March 2026 with $20M in cash and short-term deposits and remains in compliance with its debt covenants, with no principal payments due on its Callodine facility until May 2028. Net cash used in operations fell to $6.0M from $6.7M a year earlier, but management acknowledged that the current cash position limits how aggressively it can invest if revenue ramps slower than planned.

Contracted and late-stage business build revenue backlog

Management pointed to nearly $13M of contracted and late-stage business closed in 2025 and highlighted about $30M of contracted ARR in late-stage agreements. These deals are expected to begin contributing meaningfully in late 2026 and into 2027, providing a de facto backlog that investors will watch closely for conversion and ramp timing.

Early AI gains show promise for engagement

The company emphasized DarioIQ, its AI engine, as a key differentiator, citing behavioral-triggered engagement programs that delivered up to 40% better member retention and as much as 55% more active sessions versus control groups. Management argued that these early engagement lifts should translate into better outcomes, stronger customer value and improved monetization over time.

Data and clinical validation underpin strategic positioning

DarioHealth touted more than 13 billion real-world data points linked to clinical outcomes and over 100 peer-reviewed studies. This data trove is being leveraged to power AI-driven personalization and support regulatory and payer discussions, as the company pushes into outcomes- and claims-based models that may carry higher, more durable revenue streams.

Move toward care delivery via partnerships

Rather than building full clinical infrastructure, DarioHealth is partnering to move closer to care delivery, citing deeper integration with GreenKey Health for a sleep apnea pathway. This approach is designed to let the company participate in care-related and outcomes-based revenue without the heavy capital requirements of owning the entire care stack, though execution risk remains.

Consumer business shows notable momentum

Direct-to-consumer revenue was a rare bright spot, rising 42% year-over-year and 24% sequentially, driven largely by strong demand for the company’s MSK product. Management noted growing interest from international markets and clinics, suggesting that the consumer channel can be both a revenue driver and a proof point for broader enterprise adoption.

Strategic reset weighs on year-over-year revenue

Despite sequential gains, Q1 revenue declined versus the year-ago quarter as the company phased out non-recurring pharmaceutical revenue deemed non-core to its long-term model. While this strategic shift cleans up the revenue mix and focuses the business on recurring, higher-quality streams, it also depresses headline growth and complicates year-over-year comparisons.

Ongoing losses and cash needs remain investor concerns

Even with improved margins and lower OpEx, DarioHealth still posted a GAAP operating loss of $7.3M and a non-GAAP loss of $5.3M in Q1. Investors will be watching whether the combination of pipeline conversion, cost control and high-margin channel revenue is enough to narrow losses before the balance sheet forces difficult capital-raising or spending decisions.

Conversion, channel and visibility risks loom large

Management acknowledged that a substantial portion of future growth hinges on converting 2025-signed accounts and late-stage deals into active revenue, with many deployments slated for the second half of 2026 and beyond. The reliance on channel partners and large off-cycle opportunities introduces execution risk and potential volatility if implementations slip or scale more slowly than anticipated.

Strategic review adds uncertainty to the outlook

The company remains in an active strategic review overseen by a special committee and external advisors, exploring potential transactions or other options. While this could unlock value or accelerate scale, it also risks distracting management and adds another layer of uncertainty for shareholders trying to model the medium-term trajectory.

Guidance points to H2 acceleration, with caveats

Management expects revenue to accelerate in the second half of 2026 as 2025-signed accounts and late-stage contracted ARR begin to ramp, leaning on a $127M pipeline, expanded access to around 175M covered lives and improving gross margins and cash burn. However, they stopped short of offering precise numerical guidance, underscoring that timing of conversions, channel deployments and outcomes-based initiatives will determine how much of the theoretical upside materializes.

DarioHealth’s earnings call painted a picture of a company methodically rebuilding around higher-margin, data-driven digital health channels, with early wins in AI engagement and distribution reach. For investors, the story now hinges on whether management can convert a promising pipeline and disciplined cost structure into durable, profitable growth before strategic and balance-sheet constraints close the window.